null Emily McDonald, MD, M.Sc.
My research focuses on interventions related to polypharmacy, medication safety and dosing strategies. A number of my studies on the appropriate use of hospital resources, tests and treatments have been published in high-impact peer-reviewed journals and several relating to safer prescribing in older adults have been featured in the media. In 2020-2021 I participated in and led a number of high-profile COVID-19 studies. I happily supervise graduate students in the field of medication safety/optimization and have received funding from the CIHR, the Centre for Ageing and Brain Health Innovation, the Canadian Frailty Network and from the McGill Interdisciplinary Initiative in Infection and Immunity (MI-4).
Ezer N, Belga S, Daneman N, Chan A, Smith B M, Daniels S et al. Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial BMJ 2021; 375 :e068060 doi:10.1136/bmj-2021-068060.
Ross S, Wu P, Antique A, Papillon-Ferland L, Tamblyn R, Lee TC, McDonald EG. Adverse Drug Events in Older Adults: A Review of Adjudication Methods in Deprescribing Clinical Trials. JAGS. March 6th 2020 epub ahead of print. PMID: 32142161.
McDonald EG, Dendukuri N, Frenette C et al., The Impact of Private Rooms on Common Healthcare Associated Infections: A Time Series Analysis of a Complete Hospital move. JAMA Internal Medicine. Online First Aug 19, 2019. PMID: 31424489.
McDonald EG, Wu P, Rashidi B et al., The MedSafer study: a controlled trial of an electronic decision support tool for deprescribing in acute care. Journal of American Geriatrics Society. Epub 2019 Jun 27. PMID: 31250427.
McDonald EG, Milligan J, Frenette C, Lee TC. Continuous proton pump inhibitor therapy and the associated risk of recurrent Clostridium Difficile. JAMA int med, 2015 May;175(5):784-91. PMID: 25730198.